Background

Professor Heidi Drummer is Program Director for Disease Elimination and co-Head of the Viral Entry and Vaccines research group at Burnet Institute. In 2021, she was appointed as Scientific Director of the Burnet Diagnostics Initiative, a new Burnet Initiative to progress diagnostics through to human health solutions. She also leads the Hepatitis C Vaccine development stream of the Burnet Vaccine Initiative.

Heidi is an inventor on numerous granted patents and is internationally recognised as a leader in viral glycoprotein structure and function. She has developed multiple point of care diagnostic assays to measure immunity to COVID-19 and established clinical studies to examine immune response generated by SARS-CoV-2 vaccines.

Heidi has extensive experience in industry engagement and commercialisation of diagnostic assays and the translation of vaccines through pre-clinical studies into clinical trials.

Listen to Professor Drummer on Episode 2 of our How Science Matters podcast.

Appointments

• 2017: Program Director, Disease Elimination, Burnet Institute
• 2014: Deputy Head, Centre for Biomedical Research, Burnet Institute
• 2010: Adjunct Associate Professor, Department of Microbiology, Monash University, Victoria, Australia
• 2009: Honorary Senior Lecturer, Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
• 2008: Burnet Institute Principal Fellow, Victoria, Australia
• 2005: Co Head Viral Fusion Laboratory-HCV studies. Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

Positions

• 2009: Member of the Burnet Institute PhD Committee, Victoria, Australia
• 2009: Burnet Institute Honours program coordinator (co-Associate Professor Paul Gorry), Australia
• 2008: Elected Treasurer Australian Centre for Hepatitis Virology
• 2001: Principal Investigator, Australian Centre for Hepatitis and HIV Virology Research

Qualifications

• 1989: BSc (Hons), University of Melbourne, Victoria, Australia
• 1993: PhD, University of Melbourne, Australia

Awards

• 2009: Gust McKenzie Award
• 1990: Australian Postgraduate Research Award

Projects (13)

Current (11)

• 

  ACE2 inhibitors for treatment of COVID-19

• 

  Burnet COVID-19 Vaccine | Burnet Vaccine Initiative (BVI)

• 

  COVID-19 antigens for PoC test development

• 

  COVID-19 Vaccine Development

• 

  Development of a universal prophylactic vaccine for Hepatitis C

• 

  HepSeeVax: Proof-of-concept study of an HCV vaccine candidate

• 

  Neutralising antibody assays for COVID-19

• 

  Social Networks and the Hepatitis C Virus

• 

  Understanding how HCV evades the immune system

• 

  Understanding the correlates of protection for hepaciviruses

• 

  What drives hepatitis C reinfection?

Publications (106)

2023 (2)

• Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
  Howell J, Van H, Pham MD, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan GW, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson A, Drummer HE, Anderson D
  Liver Int. 2023 Jan; Epub ahead of print
• The second COVID-19 mRNA vaccine dose enhances the capacity of Spike RBD-specific memory B cells to bind Omicron BA.2.
  Hartley GE, Edwards ESJ, Varese N, Boo I, Aui PM, Bornheimer SJ, Hogarth PM, Drummer HE, O'Hehir RE, van Zelm MC
  Allergy. 2023 Jan; 78(3):855-858

2022 (5)

• Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
  Howell J, Traeger MW, Williams B, Layton C, Doyle JS, Latham N, Draper B, Bramwell F, Membrey D, McPherson M, Roney J, Stoové M, Thompson AJ, Hellard ME, Pedrana A
  Clin Liver Dis (Hoboken). 2022 Oct; 20(4):136-139
• Point-of-Care Diagnostics for Diagnosis of Active Syphilis Infection: Needs, Challenges and the Way Forward.
  Pham MD, Ong JJ, Anderson DA, Drummer HE, Stoové M
  Int J Environ Res Public Health. 2022 Jul; 19(13):8172
• A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
  Donnison T, McGregor J, Chinnakannan S, Hutchings C, Center RJ, Poumbourios P, Klenerman P, Drummer HE, Barnes E
  Hepatology. 2022 Mar; 76(4):1190-1202
• Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
  McGregor J, Hardy JM, Lay CS, Boo I, Piontek M, Suckow M, Coulibaly F, Poumbourios P, Center RJ, Drummer HE
  J Virol. 2022 Mar; 96(5): e01675-21
• An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development.
  Salas JH, Urbanowicz RA, Guest JD, Frumento N, Figueroa A, Clark KE, Keck Z, Cowton VM, Cole SJ, Patel AH, Fuerst TR, Drummer HE, Major M, Tarr AW, Ball JK, Law M, Pierce BG, Foung SKH, Bailey JR
  Gastroenterology. 2022 Feb; 162(2):562-574

2021 (8)

• A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
  Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Boo I, Center RJ, Li F, Grimley SL, Wines BD, Nguyen THO, Mordant FL, Ellenberg P, Rowntree LC, Kedzierski L, Cheng AC, Doolan DL, Matthews G, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DFJ, Anderson DA, Godfrey DI
  EBioMedicine. 2021 Dec; 74:103729
• The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research-Lessons in Scientific Community Outreach.
  Tu T, Rodrigo C, Strasser SI, Bowden DS, MacLachlan JH, Drummer HE
  Viruses. 2021 Sep; 13(9)
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report July Update)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Aug; Update 1:1-23
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (PUBLIC HEALTH REPORT)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Jul; June(Update 1):1-24
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 May; Update 1:1-27
• To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.
  Schlotthauer F, McGregor J, Drummer HE
  Viruses. 2021 Apr; 13(5):805
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Apr; Update 1:1-24
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update - COVID-19 Global Snapshots. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Mar; Update 1:1-22

2020 (9)

• Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.
  Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, Peleg AY, Boo I, Drummer HE, Hogarth PM, O'Hehir RE, van Zelm MC
  Sci Immunol. 2020 Dec; 5(54):eabf8891
• Striving for hepatitis C elimination - the role of a vaccine.
  Hellard M, Drummer H, Scott N
  Clin Infect Dis. 2020 Dec; 77(11):2991-2992
• 10th Lorne Infection and Immunity Conference 2020.
  Smith RE, Drummer HE, Hertzog PJ
  Immunol Cell Biol. 2020 Nov; 98(10):805-806
• Frequent occurrence of low-level positive autoantibodies in chronic hepatitis C.
  Deshpande P, Bundell C, McKinnon E, Hellard M, Ffrench R, Wilkinson AL, Drummer H, Gaudieri S, Lucas M
  Pathology. 2020 Jun; 52(5):576-583
• Tenth Scientific Biennial Meeting of the Australasian Virology Society-AVS10 2019.
  Helbig KJ, Bull RA, Ambrose R, Beard MR, Blanchard H, Böcking T, Chua B, Colmant AMG, Crosse KM, Purcell DFJ, Fraser J, Hayward JA, Hamilton ST, Husain M, MacDiarmid R, Mackenzie JM, Moseley GW, Nguyen THO, Quiñones-Mateu ME, Robinson K, Rodrigo C, Rodriguez-Andres J, Rudd PA, Werno A, White P, Young P, Speck P, Hibma M, Drummer HE, Tachedjian G
  Viruses. 2020 Jun; 12(6):E621
• The most promising vaccines for COVID-19. (Updated 17.6.2020)
  Cunningham A, Chappell K, Copolov D, Crabb B, Cuthbertson A, Doherty P, Drummer H, Foley C, Godfrey D, Halton J, Kelleher A , Majumdar S, McDonald C, Munro T, Purcell D, Young P
  Rapid Res Infor Forum. 2020 May
• Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine.
  Center RJ, Boo I, Phu L, McGregor J, Poumbourios P, Drummer HE
  J Biol Chem. 2020 Apr; 295(21):7179-7192
• Infectious KoRV-related retroviruses circulating in Australian bats.
  Hayward JA, Tachedjian M, Kohl C, Johnson A, Dearnley M, Jesaveluk B, Langer C, Solymosi PD, Hille G, Nitsche A, Sánchez CA, Werner A, Kontos D, Crameri G, Marsh GA, Baker ML, Poumbourios P, Drummer HE, Holmes EC, Wang LF, Smith I, Tachedjian G
  Proc Natl Acad Sci U S A. 2020 Apr; 117(7):9529–9536
• B cell immunodominance in primary hepatitis C virus infection.
  Brasher NA, Eltahla AA, Underwood A, Boo I, Rizzetto S, Walker M, Rodrigo C, Luciani F, Maher L, Drummer HE, Tedla N, Lloyd AR, Bull RA
  J Hepatol. 2020 Jan; 72(4):670-679

2019 (3)

• The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
  Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME
  BMC Med. 2019 Sep; 17(1):175
• Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.
  King HAD, Gonelli CA, Tullett KM, Lahoud MH, Purcell DFJ, Drummer HE, Poumbourios P, Center RJ
  PLoS One. 2019 Aug; 14(8):e0220986
• Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.
  Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J
  Sci Rep. 2019 Jun; 9(1):9251

2018 (4)

• Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.
  Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J
  Sci Rep. 2018 Apr; 8(1):6483
• Distinct functions for the membrane proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.
  Narasimhulu VGS, Bellamy-McIntyre AK, Laumaea AE, Lay CS, Harrison DN, King HAD, Drummer HE, Poumbourios P
  J Biol Chem. 2018 Apr; 293(16):6099-6120
• Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists.
  Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J
  Viral Immunol. 2018 Feb; 31(4):338-343
• Escape of Hepatitis C virus from epitope I neutralization increases sensitivity of other neutralization epitopes.
  Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE
  J Virol. 2018 Feb; 92(9):e02066-17

2017 (3)

• Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P, McKeating JA
  A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.
  Wellcome Open Res. 2017 Sep; 2:82
• An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry.
  McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P, Drummer HE
  J Virol. 2017 Feb; 91(5):e01668
• The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
  Vietheer P, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE
  Hepatol. 2017 Jan; Epub ahead of print

2016 (5)

• The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact.
  Boeuf P, Drummer HE, Richards JS, Scoullar MJ, Beeson JG
  BMC Med. 2016 Aug; 14(1):112
• HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-kappaB.
  Saleh S, Lu HK, Evans V, Harisson D, Zhou J, Jaworowski A, Sallmann G, Cheong KY, Mota TM, Tennakoon S, Angelovich TA, Anderson J, Harman A, Cunningham A, Gray L, Churchill M, Mak J, Drummer H, Vatakis DN, Lewin SR, Cameron PU
  Retrovirology. 2016 Jul; 13(1):49
• The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P
  PLoS One. 2016 May; 11(5):e0156213
• Calsyntenin-1 mediates hepatitis C virus replication.
  Awan Z, Tay ES, Eyre NS, Wu LE, Beard MR, Boo I, Drummer HE, George J, Douglas MW
  J Gen Virol. 2016 May; 97(8):1877-1887
• Characterisation of a hepatitis C virus like particle vaccine produced in a human hepatocyte-derived cell line.
  Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Hermann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J
  J Gen Virol. 2016 May; 97 (8):1865-1876

2015 (4)

• Monoclonal antibodies directed towards the Hepatitis C virus glycoprotein E2 detect antigenic differences modulated by HVR1, HVR2 and the igVR.
  Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Vietheer PT, Edwards S, Quinn C, Coulibaly F, Poumbourios P, Drummer HE
  J Virol. 2015 Sep; 89(24):12245-12261
• The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
  Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M
  BMC Med. 2015 Aug; 13:198
• Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection.
  Alhammad YM, Maharajh S, Butcher R, Eden JS, White PA, Poumbourios P, Drummer HE
  PLoS One. 2015 May; 10(5):e0126397
• Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014.
  Drummer HE
  Ann Transl Med. 2015 May; 3(Suppl 1):S6

2014 (4)

• Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.
  Drummer HE
  Front Microbiol. 2014 Jul; 5:329
• Antibodies to the high density lipoprotein receptor SR-B1 potently inhibit hepatitis C virus replication in vivo: New avenues for preventing reinfection of the liver following transplantation.
  Drummer HE
  Hepatology. 2014 Jun; 60(5):1463-1465
• A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.
  Beard MR, Ffrench R, Gowans EJ, Helbig KJ, Eyre NM, Douglas MMW, Grebely J, Ahlenstiel G, Locarnini S, George J, Shackel NA, White PA, Thompson AJ, Drummer H
  Gastroenterology. 2014 May; 147(1):E1-E4
• Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.
  Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M
  Hepat Mon. 2014 Jan; 14(1):e14678

2013 (4)

• High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.
  Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M
  PLoS One. 2013 Nov; 8(11):e80216
• Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41.
  Khasawneh AI, Laumaea A, Harrison DN, Bellamy-McIntyre AK, Drummer HE, Poumbourios P
  Retrovirology. 2013 Apr; 10(1):44
• Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity.
  Drummer HE, Hill MK, Maerz AL, Wood S, Ramsland PA, Mak J, Poumbourios P
  PLoS Pathog. 2013 Apr; 9(4):e1003218
• Identification of specific regions in hepatitis C virus core, NS2 and NS5A that genetically interact with p7 and co-ordinate infectious virus production.
  Gouklani H, Beyer C, Drummer H, Gowans EJ, Netter HJ, Haqshenas G
  J Viral Hepat. 2013 Apr; 20(4):e66-e71

2012 (4)

• In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.
  Davis C, Harris HJ, Hu K, Drummer HE, McKeating JA, Mullins JG, Balfe P
  Cell Microbiol. 2012 Aug; 14(12):1892-1903
• Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis.
  Gouklani H, Bull RA, Beyer C, Coulibaly F, Gowans EJ, Drummer HE, Netter HJ, White PA, Haqshenas G
  J Virol. 2012 May; 86(9):5080-5088
• The role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.
  McCaffrey K, Boo I, Tewierek K, Edmunds ML, Poumbourios P, Drummer HE
  J Virol. 2012 Apr; 86(7):3961-3974
• Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.
  Boo I, Tewierek K, Douam F, Lavillette D, Poumbourios P, Drummer HE
  Biochem J. 2012 Apr; 443(1):85-94

2011 (4)

• Role for the terminal clasp of HIV-1 gp41 in the initiation of membrane fusion.
  Lay CS, Ludlow LE, Stapleton D, Bellamy-McIntyre AK, Ramsland PA, Drummer HE, Poumbourios P
  J Biol Chem. 2011 Oct
• Hepatitis C virus (HCV) envelope glycoproteins e1 and e2 contain reduced cysteine residues essential for virus entry.
  Fraser J, Boo I, Poumbourios P, Drummer HE
  J Biol Chem. 2011 Sep; 286(37):31984-31992
• Hepatitis C Virus Glycoprotein-dependent Entry (Book Chapter)
  Drummer HE, McKeating JA
  in Hepatitis C: Antiviral Drug Discovery and Development. 2011 Jan; Ed. Tan, SL and He, YP:321-343
• The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.
  McCaffrey K, Gouklani H, Boo I, Poumbourios P, Drummer HE
  J Gen Virol. 2011 Jan; 92(Pt 1):112-121

2010 (3)

• The SR-BI partner PDZK1 facilitates hepatitis C virus entry.
  Eyre NS, Drummer HE, Beard MR
  PLoS Pathog. 2010 Oct; 6(10):e1001130
• Claudin association with CD81 defines hepatitis C virus entry.
  Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA
  J Biol Chem. 2010 Jul; 285(27):21092-21102
• Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function.
  Bellamy-McIntyre AK, Bär S, Ludlow L, Drummer HE, Poumbourios P
  Biochem Biophys Res Commun. 2010 Apr; 394(4):904-908

2009 (2)

• TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus.
  Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, McCluskey J
  Immunol Cell Biol. 2009 Aug; 87(6):464-472
• Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix.
  Cheong WS, Drummer HE, Netter HJ
  J Virol Methods. 2009 Jun; 158(1-2):35-40

2008 (2)

• High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
  Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hetlard M
  Hepatology. 2008 Dec; 48(6):1746-1752
• Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
  Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA
  J Virol. 2008 Dec; 82(24):12020-12029

2007 (10)

• Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.
  McCaffrey K, Boo I, Poumbourios P, Drummer HE
  J Virol. 2007 Sep; 81(17):9584-9590
• An N-terminal glycine-rich sequence contributes to retrovirus trimer of hairpins stability.
  Wilson KA, Maerz AL, Bar S, Drummer HE, Poumbourios P
  Biochem Biophys Res Commun. 2007 Aug; 359(4):1037-1043
• Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion.
  Bellamy-McIntyre AK, Lay CS, Bar S, Maerz AL, Talbo GH, Drummer HE, Poumbourios P
  J Biol Chem. 2007 Aug; 282(32):23104-23116
• Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
  Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwaj M, Bowden S, Torresi J, Drummer H.
  J Clin Virol. 2007 Aug; 39(4):288-294
• A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus.
  Torresi J, Stock OM, Fischer AE, Grollo L, Drummer H, Boo I, Zeng W, Earnest-Silveira L, Jackson DC
  Hepatology. 2007 Apr; 45(4):911-920
• Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1.
  Drummer HE, Boo I, Poumbourios P
  J Gen Virol. 2007 Apr; 88(Pt 4):1144-1148
• Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes.
  Torresi J, Fischer A, Grollo L, Zeng W, Drummer H, Jackson DC
  Immunol Cell Biol. 2007 Feb; 85(2):169-173
• Transient and stable expression of the HCV envelope glycoproteins in cell lines and primary hepatocytes transduced with a recombinant baculovirus.
  Martyn JC, Dong X, Holmes-Brown S, Pribul P, Li S, Drummer HE, Gowans EJ
  Arch Virol. 2007 Feb; 152(2):329-343
• Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.
  Poumbourios P, Drummer HE
  Antivir Chem Chemother. 2007 Jan; 18(4):169-189
• Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
  Vietheer PT, Boo I, Drummer HE, Netter HJ
  Antivir Ther. 2007 Jan; 12(4):477-487

2006 (2)

• A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.
  Drummer HE, Boo I, Maerz AL, Poumbourios P
  J Virol. 2006 Aug; 80(16):7844-7853
• Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
  Grollo L, Torresi J, Drummer H, Zeng W, Williamson N, Jackson DC
  Antivir Ther. 2006 Jan; 11(8):1005-1014

2005 (1)

• Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2.
  Drummer HE, Wilson KA, Poumbourios P
  Biochem Biophys Res Commun. 2005 Mar; 328(1):251-257

2004 (2)

• Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry.
  Heidi E Drummer, Pantelis Poumbourios
  J Biol Chem. 2004 Jul; 279(29):30066-30072
• Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core.
  Chan-Sien Lay, Kirilee A Wilson, Bostjan Kobe, Bruce E Kemp, Heidi E Drummer, Pantelis Poumbourios
  FEBS Lett. 2004 Jun; 567(2-3):183-188

2003 (2)

• Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41.
  Pantelis Poumbourios, Anne L Maerz, Heidi E Drummer
  J Biol Chem. 2003 Oct; 278(43):42149-42160
• Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins.
  Heidi E Drummer, Anne Maerz, Pantelis Poumbourios
  FEBS Lett. 2003 Jul; 546(2-3):385-390

2002 (1)

• Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.
  Heidi E Drummer, Kirilee A Wilson, Pantelis Poumbourios
  J Virol. 2002 Nov; 76(21):11143-11147

2001 (5)

• Sequence conservation and antigenic variation of the structural proteins of equine rhinitis A virus.
  A Varrasso, H E Drummer, J A Huang, R A Stevenson, N Ficorilli, M J Studdert, C A Hartley
  J Virol. 2001 Nov; 75(21):10550-10556
• Identification of equine herpesvirus 3 (equine coital exanthema virus), equine gammaherpesviruses 2 and 5, equine adenoviruses 1 and 2, equine arteritis virus and equine rhinitis A virus by polymerase chain reaction.
  K Dynon, A Varrasso, N Ficorilli, S Holloway, G Reubel, F Li, C Hartley, M Studdert, H Drummer
  Aust Vet J. 2001 Oct; 79(10):695-702
• Identification of equine herpesviruses 1 and 4 by polymerase chain reaction.
  A Varrasso, K Dynon, N Ficorilli, C A Hartley, M J Studdert, H E Drummer
  Aust Vet J. 2001 Aug; 79(8):563-569
• Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
  A L Maerz, H E Drummer, K A Wilson, P Poumbourios
  J Virol. 2001 Jul; 75(14):6635-6644
• Equine rhinitis A virus: structural proteins and immune response.
  C A Hartley, N Ficorilli, K Dynon, H E Drummer, J A Huang, M J Studdert
  J Gen Virol. 2001 Jul; 82(Pt 7):1725-1728

2000 (1)

• Analysis of equine herpesvirus 2 strain variation using monoclonal antibodies to glyucoprotein B.
  S A Holloway, G J Lindquester, M J Studdert, H E Drummer
  Arch Virol. 2000 Jan; 145(8):1699-1713

1999 (4)

• Epidemiological studies of equine herpesvirus 1 (EHV-1) in Thoroughbred foals: a review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997.
  J R Gilkerson, J M Whalley, H E Drummer, M J Studdert, D N Love
  Vet Microbiol. 1999 Aug; 68(1-2):15-25
• Epidemiology of EHV-1 and EHV-4 in the mare and foal populations on a Hunter Valley stud farm: are mares the source of EHV-1 for unweaned foals.
  J R Gilkerson, J M Whalley, H E Drummer, M J Studdert, D N Love
  Vet Microbiol. 1999 Aug; 68(1-2):27-34
• Identification, sequence analysis and characterisation of equine herpesvirus 5 glycoprotein B.
  S A Holloway, G J Lindquester, M J Studdert, H E Drummer
  Arch Virol. 1999 Jan; 144(2):287-307
• The nucleotide sequence of the glycoprotein G homologue of equine herpesvirus 3 (EHV3) indicates EHV3 is a distinct equid alphaherpesvirus.
  C A Hartley, H E Drummer, M J Studdert
  Arch Virol. 1999 Jan; 144(10):2023-2033

1998 (3)

• Seroprevalence of equine herpesvirus 1 in thoroughbred foals before and after weaning.
  J R Gilkerson, D N Love, H E Drummer, M J Studdert, J M Whalley
  Aust Vet J. 1998 Oct; 76(10):677-682
• Characterization of glycoprotein B of the gammaherpesvirus equine herpesvirus-2.
  S A Holloway, M J Studdert, H E Drummer
  J Gen Virol. 1998 Jul; 79 ( Pt 7):1619-1629
• Equine herpesvirus-4 glycoprotein G is secreted as a disulphide-linked homodimer and is present as two homodimeric species in the virion.
  H E Drummer, M J Studdert, B S Crabb
  J Gen Virol. 1998 May; 79 ( Pt 5):1205-1213

1997 (1)

• Identification of noncytopathic equine rhinovirus 1 as a cause of acute febrile respiratory disease in horses.
  F Li, H E Drummer, N Ficorilli, M J Studdert, B S Crabb
  J Clin Microbiol. 1997 Apr; 35(4):937-943

1996 (1)

• Equine gammaherpesvirus 2 (EHV2) is latent in B lymphocytes.
  H E Drummer, G H Reubel, M J Studdert
  Arch Virol. 1996 Jan; 141(3-4):495-504

1995 (2)

• Application of an equine herpesvirus 1 (EHV1) type-specific ELISA to the management of an outbreak of EHV1 abortion.
  H E Drummer, A Reynolds, M J Studdert, C M MacPherson, B S Crabb
  Vet Rec. 1995 Jun; 136(23):579-581
• A type-specific serological test to distinguish antibodies to equine herpesviruses 4 and 1.
  B S Crabb, C M MacPherson, G H Reubel, G F Browning, M J Studdert, H E Drummer
  Arch Virol. 1995 Jan; 140(2):245-258

1994 (2)

• Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones.
  D C Jackson, H E Drummer, L Urge, L Jr Otvos, L E Brown
  Virology. 1994 Mar; 199(2):422-430
• Conserved determinants for CD4+ T cells within the light chain of the H3 hemagglutinin molecule of influenza virus.
  D C Jackson, H E Drummer, L E Brown
  Virology. 1994 Feb; 198(2):613-623

1993 (2)

• A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus.
  G P Kapaklis-Deliyannis, H E Drummer, L E Brown, G A Tannock, D C Jackson
  Electrophoresis. 1993 Sep; 14(9):926-936
• Modulation of CD4+ T-cell recognition of influenza hemagglutinin by carbohydrate side chains located outside a T-cell determinant.
  H E Drummer, D C Jackson, L E Brown
  Virology. 1993 Jan; 192(1):282-289

1989 (1)

• Class II-restricted T-cell clones to a synthetic peptide of influenza virus hemagglutinin differ in their fine specificities and in the ability to respond to virus.
  R A Ffrench, X L Tang, E M Anders, D C Jackson, D O White, H Drummer, J D Wade, G W Tregear, L E Brown
  J Virol. 1989 Jul; 63(7):3087-3094

News Articles (68)

2023 (1)

• International podcast award for How Science Matters

2022 (7)

• 2022 in Review: July to December
• How Science Matters nominated for Australian Podcast Award
• Burnet welcomes grant for mRNA vaccine development
• Burnet awarded grant to develop next generation liver test
• Prestigious grant to profile responses to COVID-19 vaccines in vulnerable people
• Vale Professor Ruth Bishop AC
• Burnet Institute partners with Moderna to develop novel mRNA vaccines

2021 (16)

• 2021 in Review: July to December
• Burnet secures $3m funding to help bolster COVID-19 pandemic protections
• Victoria to become home of mRNA vaccine manufacturing
• Omicron variant
• Rapid COVID-19 test a Burnet collaboration
• Podcast Ep. 2: Are vaccines the silver bullet?
• The path to exiting the pandemic is paved with vaccinations
• COVID-19 Global Update: 1-31 May 2021
• COVID-19 Global Update: Vaccines and Variants
• Professor Heidi Drummer appointed Scientific Director of Burnet Diagnostics Initiative (BDI)
• COVID-19 Timeline: How Science Matters
• Your vaccine questions answered
• How long will COVID-19 vaccinations remain protective?
• Burnet hosts Thai Ambassador
• Talking vaccines: Professor Heidi Drummer with ABC Melbourne's Raf Epstein
• Australia’s little-recognised vaccine advantage

2020 (7)

• 2020 in Review: January to June
• Athena SWAN Bronze Award for Burnet Institute
• IMPACT special edition now online!
• Nobel Prize for hepatitis C discovery
• MRFF funding for Burnet COVID research
• Burnet a knowledge hub for COVID-19
• New virus in bats linked to AIDS-like disease decimating koalas

2019 (4)

• ACH2 grants a terrific outcome
• The case for a hepatitis C vaccine
• Primary healthcare effort needed to achieve hep C elimination
• The case for a Hep C vaccine

2018 (2)

• Hepatitis elimination efforts in great hands
• ACH2 grants for Burnet research

2017 (9)

• Burnet's leaders in virology
• Burnet excels in NHMRC funding
• Burnet researcher elected president of ACHV
• Burnet research at World Congress on Public Health
• Drug resistance a growing threat
• Health challenges for women in PNG focus of IWD lunch
• Hep C virus exposed to attack
• Winning battles for gender equity
• The path to disease elimination

2016 (11)

• IMPACT: latest edition now out!
• Hep C: Elimination is the Goal
• Prestigious 2016 Frank Fenner Award for Heidi Drummer
• Zika impact may be hidden: study
• Burnet launches Eliminate Hep C strategy
• Burnet Institute and ARTES join forces to develop novel hepatitis C vaccine
• 2020 vision for Hep C elimination
• Burnet commits to gender equity
• Australia a potential world leader to eliminate hepatitis C
• IWD reflections
• Gender equity Burnet's theme for International Women's Day

2015 (2)

• Burnet's NHMRC success rate among Australia's best
• Burnet celebrates International Women's Day

2014 (3)

• 2014 In Review: July - December
• New appointment for Associate Professor Heidi Drummer
• Burnet Institute researchers acknowledged in NHMRC funding round

2013 (2)

• Congratulations to Burnet's NHMRC grant recipients
• New drugs and an effective vaccine could lead to hepatitis C eradication

2012 (2)

• Burnet NHMRC grants announcement
• Major breakthrough in hepatitis C vaccine development

2011 (2)

• Burnet NHMRC grant recipients 2012
• Burnet's work featured in 'Bodies of Work' liftout - The Saturday Age